To Evaluate and compare effect and skin safety of Clobetasol gel (Clobetasol Propionate USP 0.05% w/w) and Clobetasol Cream (Clobetasol Propionate BP 0.05% w/w) in patients with mild to moderate psoriasis

Evaluation and comparison of efficacy and in use skin safety of Clobetasol gel (Clobetasol Propionate USP 0.05% w/w) and Clobetasol Cream (Clobetasol Propionate BP 0.05% w/w) in patients with mild to moderate psoriasis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2013/02/003430

Enrollment

Registered

2013-02-25

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- mild to moderate Psoriasis

Interventions

Intervention1: Clobetasol Gel (Clobetasol Propionate USP 0.05% w/w with Tetrahydropiperine 0.5% ): Apply Vaseline Petroleum Jelly over the affected areas. Apply approximately 0.25-0.5 gms of Clobetas

Eligibility

Inclusion criteria

Inclusion criteria: 1. Voluntary men/women with clinically diagnosed mild to moderate stable, chronic, plaque psoriasis. 2. 2. At least one, discrete, well circumscribed lesion approximately 20 cm2 â?? 80 cm2 on trunk separated from adjacent lesions by at least 3 cms.The same lesion will be tracked through the entire study. 3. Age between 18 â?? 55 years 4. Not on treatment for psoriasis- oral since 1 month and topical since 2 weeks. 5. Accepting not to use products with the same end benefit during the entire study duration. 6. Cooperating, informed of the need and duration of the examinations, and ready to comply with protocol procedures. 7. Having signed a Consent Form and will be informed orally and in writing of all information concerning the study procedures and study objectives.

Exclusion criteria

Exclusion criteria: 1. Pustular psoriasis, Palmoplanter and erythrodermic psoriasis. 2. Pregnant women (as confirmed by UPT) and lactating women. 3. History of allergic dermatitis or contact allergy to cosmetics, 4. Hypersensitivity to any cosmetic product, raw material. 5. For whom the Investigator considers that he/she will not be compliant with study procedures. 6. Any clinically significant systemic or cutaneous disease, which may interfere with study treatments or procedures. 7. Subjects on any medical treatment either systemic or topical which may interfere with the performance of the study treatment (presently or in the past 1 month). 8. Subject in an exclusion period or participating in another similar cosmetic or therapeutic trial.

Design outcomes

Primary

Measure	Time frame
â?¢ Clinical Evaluation using LASI scale.Timepoint: â?¢Day 0, 10 days,20 days and 30 days	—

Secondary

Measure	Time frame
In use skin safety of Clobetasol gel (Clobetasol Propionate USP 0.05% w/w) and Clobetasol Cream (Clobetasol Propionate BP 0.05% w/w).Timepoint: â?¢Day 0, 10 days,20 days and 30 days	—

Countries

India

Contacts

Public ContactMs Prachi Parihar Saxena

SHRI RATNAKAR CLINIC

nandutorse@yahoo.com9820338816

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026